AKT1 and metabolic dysfunction-associated steatotic liver disease: The results for MET’s inhibitory effect on Akt mRNA are consistent with previous studies that showed that MET treatment suppresses the PI3K/AKT signaling in both cancer and NAFLD patients [28,29].